Details of the Drug Combinations

General Information of This Drug (ID: DMI5OXG)

Drug Name

Latanoprost DMI5OXG

Synonyms

Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate

Indication

Disease Entry	ICD 11	Status	REF
Ocular hypertension	9C61.01	Approved	[1]
Open-angle glaucoma	9C61	Approved	[2]
OPTN-related open angle glaucoma	N.A.	Approved	[1]
Glaucoma/ocular hypertension	9C61	Phase 2	[3]
Ocular disease	1F00.1Z	Investigative	[4]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tafluprost + Latanoprost	DCBPPPU	Tafluprost	Glaucoma, Primary Open Angle	[5]
Taprenepag + Latanoprost	DCA1TWQ	Taprenepag	Glaucoma, Open-Angle	[6]
Taprenepag + Latanoprost	DCA57J9	Taprenepag	Primary Open-Angle Glaucoma	[7]
Latanoprost + INO-8875	DCG2BG2	INO-8875	Primary Open-Angle Glaucoma (POAG)	[8]
Brinzolamide + Latanoprost	DC72YFX	Brinzolamide	Ocular Hypertension	[9]
------------------------------------------------------------------------------------

References

1	Latanoprost FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1961).
3	Clinical pipeline report, company report or official report of Mati therapeutics.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344).
5	ClinicalTrials.gov (NCT04737928) Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
6	ClinicalTrials.gov (NCT00934089) A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
7	ClinicalTrials.gov (NCT00572455) Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
8	ClinicalTrials.gov (NCT01917383) A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
9	ClinicalTrials.gov (NCT01937312) Effect of SIMBRINZA Suspension as an Added Therapy to a Prostaglandin Analogue